Principal Financial Group Inc. raised its holdings in Chemours Company (The) (NYSE:CC) by 5.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 794,592 shares of the specialty chemicals company’s stock after purchasing an additional 40,095 shares during the quarter. Principal Financial Group Inc. owned 0.43% of Chemours Company (The) worth $30,131,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Ameritas Investment Partners Inc. boosted its holdings in shares of Chemours Company (The) by 349.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 69,460 shares of the specialty chemicals company’s stock valued at $2,674,000 after purchasing an additional 53,991 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in shares of Chemours Company (The) in the 1st quarter valued at $917,000. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Chemours Company (The) by 60.5% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,325 shares of the specialty chemicals company’s stock valued at $974,000 after purchasing an additional 9,549 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Chemours Company (The) in the 1st quarter valued at $450,000. Finally, Victory Capital Management Inc. boosted its holdings in shares of Chemours Company (The) by 292.0% in the 2nd quarter. Victory Capital Management Inc. now owns 657,810 shares of the specialty chemicals company’s stock valued at $24,944,000 after purchasing an additional 489,990 shares in the last quarter. 72.90% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Chemours Company (NYSE CC) opened at 49.71 on Friday. Chemours Company has a 12-month low of $12.47 and a 12-month high of $51.51. The company’s 50 day moving average price is $47.45 and its 200 day moving average price is $40.70. The firm has a market cap of $9.19 billion, a P/E ratio of 32.53 and a beta of 3.64.

Chemours Company (The) (NYSE:CC) last announced its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business earned $0.27 earnings per share. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. Equities research analysts forecast that Chemours Company will post $3.51 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 17th will be given a $0.03 dividend. The ex-dividend date is Tuesday, August 15th. This represents a $0.12 annualized dividend and a yield of 0.24%. Chemours Company (The)’s dividend payout ratio (DPR) is presently 8.11%.

In related news, VP Amy Trojanowski sold 2,500 shares of the company’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.03, for a total value of $115,075.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider E Bryan Snell sold 10,000 shares of the company’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $46.24, for a total transaction of $462,400.00. The disclosure for this sale can be found here. Insiders sold 38,837 shares of company stock valued at $1,865,603 over the last quarter. 1.14% of the stock is owned by company insiders.

A number of equities research analysts have weighed in on the company. BidaskClub raised Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Thursday, August 24th. Argus reaffirmed a “buy” rating and issued a $55.00 target price (up previously from $50.00) on shares of Chemours Company (The) in a report on Thursday, August 10th. UBS AG raised Chemours Company (The) from a “sell” rating to a “neutral” rating and raised their target price for the company from $36.00 to $50.00 in a report on Monday, August 7th. J P Morgan Chase & Co raised their target price on Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a report on Friday, August 4th. Finally, Citigroup Inc. raised their target price on Chemours Company (The) from $45.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 4th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $51.50.

ILLEGAL ACTIVITY WARNING: “Chemours Company (The) (CC) Shares Bought by Principal Financial Group Inc.” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/09/chemours-company-the-cc-shares-bought-by-principal-financial-group-inc.html.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.